SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-027524
Filing Date
2021-05-13
Accepted
2021-05-13 16:05:29
Documents
13
Period of Report
2021-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tptx-8k_20210512.htm   iXBRL 8-K 49640
2 EX-10.1 tptx-ex101_6.htm EX-10.1 27395
  Complete submission text file 0001564590-21-027524.txt   214473

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tptx-20210512.xsd EX-101.SCH 5800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20210512_lab.xml EX-101.LAB 19673
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20210512_pre.xml EX-101.PRE 11652
6 EXTRACTED XBRL INSTANCE DOCUMENT tptx-8k_20210512_htm.xml XML 3575
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 21919559
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences